Business

Bristol-Myers Squibb could pay a total of up to $444 million to acquire Galecto Biotech and its TD139 inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF), plus potential milestones. The newly announced… Read more . . .

Grupo Ferrer Internacional, which markets Alexza Pharmaceuticals’ Adasuve inhaled loxapine in the EU, Latin America, and the CIS countries, will acquire 2 million shares of Alexza common stock at $4 per share, the companies have… Read more . . .

Ferring Pharmaceuticals has announced that it has reacquired desmopressin acetate (DDAVP), which is approved as a nasal spray and a number of other formulations, from Sanofi. Ferring originally developed desmopressin, which is a synthetic form… Read more . . .

Retrophin has announced that Turing Pharmaceuticals will pay $3 million up front for three of Retrophin’s products, including Syntocinon oxytocin nasal spray and ketamine. According to the company, the agreement includes the resignation of Retrophin… Read more . . .

Boehringer Ingelheim has announced that the Striverdi Respimat olodaterol soft mist inhaler is now available in the United States. The FDA approved Striverdi Respimat for the treatment of COPD in July 2014. The company said… Read more . . .

Teva Pharmaceutical has completed a strategic review of its core therapeutic areas and will focus its development efforts on central nervous system and respiratory drugs, the company has announced. According to the announcement, 14 drug… Read more . . .

According to Lightlake Therapeutics, an investor will receive a 0.98% interest in the company’s naloxone nasal spray for the treatment of opioid overdose for a $500,000 investment and a 1% interest in intranasal naloxone for… Read more . . .